Molecular markers in gastric cancer: Can p53 and bcl-2 protein expressions be used as prognostic factors?

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3629-3636

  Zafirellis, Kyriakos ^a,c   Karameris, Andreas ^b   Milingos, Nikolaos ^a   Androulakis, George ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b Veterans Administration Hospital NIMTS   (Greece)

^c NONE   (Greece)

Author keywords

bcl 2 protein; Gastric cancer; Immunohistochemistry; p53 protein; Prognosis

Indexed keywords

MOLECULAR MARKER; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 23344436292     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Pisani P, Parkin DM, Bray F and Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83: 18-29, 1999.
2. Hansson LE, Sparen P and Nyren O: Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg 230: 162-169, 1999.
3. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
4. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
5. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
6. Hall PA and Lane DP: p53 in tumour pathology: can we trust immunohistochemistry? - Revisited! J Pathol 772: 1-4, 1994.
7. Gabbert HE, Muller W, Schneiders A, Meier S and Hommel G: The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 76: 720-726, 1995.
8. Martin HM, Filipe MI, Morris RW, Lane DP and Silvestre F: p53 expression and prognosis in gastric carcinoma. Int J Cancer 50: 859-862, 1992.
9. Tsujimoto Y, Ikegaki N and Croce CM: Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 2: 3-7, 1987.
10. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res 53: 4701-4714, 1993.
11. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F and Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
12. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC and Mason DY: Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 329: 690-694, 1993.
13. Sinicrope FA, Hart J, Michelassi F and Lee JJ: Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1: 1103-1110, 1995.
14. Inada T, Kikuyama S, Ichikawa A, Igarashi S and Ogata Y: Bcl-2 expression as a prognostic factor of survival of gastric carcinoma. Anticancer Res 18: 2003-2010, 1998.
15. Muller W, Schneiders A, Hommel G and Gabbert HE: Prognostic value of bcl-2 expression in gastric cancer. Anticancer Res 18: 4699-4704, 1998.
16. International Union Against Cancer: TNM Classification of Malignant Tumours. In: Sobin LH, Wittekind Ch (eds.). 6th ed. New York, Wiley-Liss, pp. 65-68, 2002.
17. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64: 331-349, 1965.
18. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ and Kim JP: Prognostic significance of Bcl-2 and p53 expression in gastric cancer. Int J Colorectal Dis 18: 518-525, 2003.
19. Maehara Y, Tomoda M, Hasuda S, Kabashima A, Tokunaga E, Kakeji Y and Sugimachi K: Prognostic value of p53 protein expression for patients with gastric cancer - a multivariate analysis. Br J Cancer 79: 1255-1261, 1999.
20. Matturri L, Biondo B, Cazzullo A, Colombo B, Giordano F, Guarino M, Pallotti F, Turconi P and Lavezzi AM: Prognostic significance of different biological markers (DNA index, PCNA index, apoptosis, p53, karyotype) in 126 adenocarcinoma gastric biopsies. Anticancer Res 18: 2819-2825, 1998.
21. Motojima K, Furui J, Kohara N, Ito T and Kanematsu T: Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery 116: 890-895, 1994.
22. Setala L, Kosma VM, Lipponen P, Naukkarinen A, Nordling S, Hollmen S, Eskelinen M, Syrjanen K and Alhava E: Clinical relevance of p53 index and expression of proliferating cell nuclear antigen and Ki-67 in gastric cancer. J Cancer Res Clin Oncol 124: 497-502, 1998.
23. Roviello F, Marrelli D, Vindigni C, De Stefano A, Spina D and Pinto E: P53 accumulation is a prognostic factor in intestinal-type gastric carcinoma but not in the diffuse type. Ann Surg Oncol 6: 739-745, 1999.
24. Baas IO, van den Berg FM, Mulder JW, Clement MJ, Slebos RJ, Hamilton SR and Offerhaus GJ: Potential false-positive results with antigen enhancement for immunohistochemistry of the p53 gene product in colorectal neoplasms. J Pathol 178: 264-267, 1996.
25. Jacobs TW, Prioleau JE, Stillman IE and Schnitt SJ: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054-1059, 1996.
26. Vojtesek B, Bartek J, Midgley CA and Lane DP: An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 757: 237-244, 1992.
27. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B and Hamilton SR: An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 772: 5-12, 1994.
28. Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK and Iacopetta BJ: Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27: 1050-1055, 1996.
29. Hong SI, Hong WS, Jang JJ, Lee DS, Cho NS, Jung ME, Kim HB, Ha GW, Park IC and Cho DS: Alterations of p53 gene in primary gastric cancer tissues. Anticancer Res 14: 1251-1255, 1994.
30. Seta T, Imazeki F, Yokosuka O, Saisho H, Suzuki T, Koide Y and Isono K: Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. Dig Dis Sci 43: 279-289, 1998.
31. Tahara E: Genetic Pathways of Two Types of Gastric Cancer. IARC Sci Publ, pp. 327-349, 2004.
32. van der Woude CJ, Kleibeuker JH, Tiebosch AT, Homan M, Beuving A, Jansen PL and Moshage H: Diffuse and intestinal type gastric carcinomas differ in their expression of apoptosis related proteins. J Clin Pathol 56: 699-702, 2003.
33. Bell SM, Scott N, Cross D, Sagar P, Lewis FA, Blair GE, Taylor GR, Dixon MF and Quirke P: Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57-64, 1993.
34. McLaren R, Kuzu I, Dunnill M, Harris A, Lane D and Gatter KC: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66: 735-738, 1992.
35. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V and Horsfall DJ: Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer 69: 135-141, 1996.
36. Ishida H, Irie K, Itoh T, Furukawa T and Tokunaga O: The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 80: 1034-1045, 1997.
37. Jansen RL, Joosten-Achjanie SR, Volovics A, Arends JW, Hupperets PS, Hillen HF and Schouten HC: Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res 18: 4455-4462, 1998.
38. Manne U, Myers RB, Moron C, Poczatek RB, Dillard S, Weiss H, Brown D, Srivastava S and Grizzle WE: Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346-358, 1997.
39. Muller W and Borchard F: Prognostic influence of p53 expression in gastric cancer. J Pathol 775: 255-258, 1996.
40. Joypaul BV, Hopwood D, Newman EL, Qureshi S, Grant A, Ogston SA, Lane DP and Cuschieri A: The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 69: 943-946, 1994.
41. Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA and Stern PL: The clinical significance of p53 accumulation in gastric carcinoma. Cancer 77: 2005-2012, 1996.
42. Aizawa K, Ueki K, Suzuki S, Yabusaki H, Kanda T, Nishimaki T, Suzuki T and Hatakeyama K: Apoptosis and Bcl-2 expression in gastric carcinomas: correlation with clinicopathological variables, p53 expression, cell proliferation and prognosis. Int J Oncol 14: 85-91, 1999.
43. Saegusa M, Takano Y and Okayasu I: Bcl-2 expression and its association with cell kinetics in human gastric carcinomas and intestinal metaplasia. J Cancer Res Clin Oncol 121: 357-363, 1995.
44. Alsabeh R, Wilson CS, Ahn CW, Vasef MA and Battifora H: Expression of bcl-2 by breast cancer: a possible diagnostic application. Mod Pathol 9: 439-444, 1996.
45. Lauwers GY, Scott GV and Karpeh MS: Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 75: 2209-2213, 1995.
46. Upadhyay S, Li G, Liu H, Chen YQ, Sarkar FH and Kim HR: Bcl-2 suppresses expression of p21WAF1/CIP1 in breast epithelial cells. Cancer Res 55: 4520-4524, 1995.
47. Gorczyca W, Markiewski M, Kram A, Tuziak T and Domagala W: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction. Virchows Arch 426: 229-233, 1995.
48. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.